HBP — Helix Biopharma Income Statement
0.000.00%
Last trade - 00:00- CA$166.50m
- CA$166.36m
- 16
- 23
- 81
- 34
Annual income statement for Helix Biopharma, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | 2025 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.13 | 6.04 | 6.33 | 9.24 | 5.4 |
| Operating Profit | -9.13 | -6.04 | -6.33 | -9.24 | -5.4 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.57 | -6.56 | -6.29 | -9.26 | -5.21 |
| Net Income After Taxes | -9.57 | -6.56 | -6.29 | -9.26 | -5.21 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -8.04 | -6.56 | -6.29 | -9.26 | -5.21 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.04 | -6.56 | -6.29 | -9.26 | -5.21 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.347 | -0.22 | -0.163 | -0.208 | -0.094 |